There are currently 14 COVID-19 vaccines under review by Health Canada, with some of them being created in this country.
One expert says Medicago’s shot is showing very promising results in its late-stage trials.
The Quebec-based company began phase three of human testing in March, intending to share results later this year.
Dr. Omar Khan, a professor of biomedical engineering at the University of Toronto, says this vaccine uses plant-based technology, unlike any other vaccine currently approved for use in Canada.
He also says the plant-based technology, which he explains is easily recognized by the immune system but is completely non-infectious, is easier to make around the world.
If approved, Medicago expects to be able to produce up to 80 million doses of its vaccine every year. That number goes up to a billion doses, once its large-scale factory is completed in 2023.
Medicago’s vaccine candidate is made in partnership with GlaxoSmithKline (GSK).
Health Canada received the first portion of Medicago’s vaccine submission for review in April.
This content is also available in: Tiếng Việt